Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 3/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.32 |
| ▸ | NR0B2 | Q15466 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 2/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448239 | 0.87 | RARB (0.39) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL6457169 | 0.85 | RARB (0.33) | IKBKBRARBHDAC11HDAC2HDAC7 | |
| SCHEMBL6448147 | 0.84 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL6448150 | 0.84 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL6452220 | 0.82 | BRD4 (0.36) | RARBHDAC11HDAC2HDAC7HDAC8 | |
| SCHEMBL6448127 | 0.82 | RARB (0.34) | IKBKBRARBHDAC11HDAC2HDAC7 | |
| SCHEMBL6449408 | 0.75 | PTPN11 (0.53) | PTPN11 | |
| SCHEMBL6449412 | 0.75 | PTPN11 (0.53) | PTPN11 | |
| SCHEMBL6452478 | 0.74 | KCNA3 (0.34) | RARBHDAC11HDAC2PTPN11NR0B2 | |
| SCHEMBL6449246 | 0.74 | ALDH1A1 (0.35) | IKBKBRARBHDAC11HDAC2HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | IKBKB 2932/4885RARB 401/4885HDAC11 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.